Guía consensada por la Sociedad Cubana de Endocrinología para el diagnóstico y tratamiento del síndrome de ovario poliquístico

Gilda Monteagudo Peña, Gisel Ovies Carballo, Manuel Gómez Alzugaray, Maité Cabrera Gámez, Kenia Rodríguez Martínez, grupo para el consenso de la Sociedad Cubana de Endocrinología

Texto completo:

PDF

Resumen

El síndrome de ovario poliquístico (SOP) es un trastorno con alta prevalencia en la práctica clínica que, por sí mismo o por las comorbilidades que se le asocian, tiene amplias implicaciones para la salud de quienes lo padecen. Es común que se presente con un patrón de heredabilidad familiar, que se exprese desde edades tempranas y tenga un agravamiento progresivo en sus manifestaciones clínicas. Existe la posibilidad de prevenir o minimizar sus efectos pero es esencial el diagnóstico temprano y el tratamiento correcto y oportuno. Por la importancia del tema y el interés por establecer pautas nacionales de atención, en junio de 2015 se realizó en La Habana el Consenso Cubano sobre Síndrome de Ovario Poliquístico, auspiciado por la Sociedad Cubana de Endocrinología. El informe del consenso se revisó y se actualizó en 2020 y se presenta a continuación como una guía para el diagnóstico y tratamiento de estas mujeres.

Referencias

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary síndrome. Hum Reprod. 2018;33(9):1602-18. DOI: https://doi.org/10.1093/humrep/dey256.

Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GE (Eds). Polycystic Ovary Syndrome (Current Issues in Endocrinology and Metabolism). Blackwell Scientific Inc.: Boston; 1992. p.377.

ESHRE/ASRM - Sponsored consensus workshop group. Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. DOI: https://doi.org/10.1016/j.fertnstert.2003.10.004.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Position Statement: Criteria for defining Polycystic Ovary Syndrome as a predominantly hyperandrogenyc syndrome: An Androgen Excess Society Guideline. J Clin Endocrinol Metab. 2006;91(11):4237-45. DOI: https://doi.org/10.1210/jc.2006-0178.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et a. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-88. DOI: https://doi.org/10.1016/j.fertnstert.2008.06.035.

Azziz R. Polycystic Ovary Syndrome. Obstet Gynecol, 2018;132(2):321-36. DOI: https://doi.org/10.1097/AOG.0000000000002698.

Legro R. Diagnostic criteria polycystic ovary syndrome. Sem Reprod Med. 2003;21(3):267-75. DOI: https://doi.org/10.1055/s-2003-43304

Pasquali R, Diamanti-Kandarakis E, Gambineri A. Management of endocrine disease: secondary polycystic ovary syndrome: theoretical and practical aspects. Eur J Endocrinol. 2016;175(4):R157-69. DOI: https://doi.org/10.1530/EJE-16-0374.

Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. Int J Environ Res Public Health. 2018;15:2589-602. DOI: https://doi.org/10.3390/ijerph15112589

Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016; 106(01):6-15. DOI: https://doi.org/10.1016/j.fertnstert.2016.05.003

Vallejo R, Rosa ME, Gómez P, Ortega E, Panadero FJ. Síndrome de ovario poliquístico. Panorama Actual Med. 2019 [acceso: 24/05/2020];43(421):1-8. Disponible en: https://botplusweb.portalfarma.com/documentos/2019/3/28/132252.pdf

Suarez BH, Borja PE, Vela MA, Ontaneda CF. Diagnóstico y manejo del síndrome de ovario poliquístico. Recimundo. 2019;3(3):970-1004. DOI: https://doi.org/10.26820/recimundo/3.

Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41. DOI: https://doi.org/10.1186/1741-7015-8-41

BarbieriR, Ehrmann D. Clinical manifestations of polycystic ovary syndrome in adults. Hum Reprod Update. 2009 [acceso: 24/05/2020]. Disponible en: https://www.uptodate.com/contents/clinical-manifestations-of-polycystic-ovary-syndrome-in-adults/print?search=sindrome

Schurmana L, Gonzalez M, Leidermanb SM, Calvar CE, Curriá MI, Fernández GI, et al. Hiperandrogenismo. Rev Argent Endocrinol Metb. 2016;53(2):45-50. DOI: https://doi.org/10.1016/j.raem.2016.05.008

Sekhon AK, Zergham AS, Tserenpil G, Mebasher A, Malik BH. The association between polycystic ovary syndrome and its dermatological manifestations. Cureus. 2020;12(2):e6855. DOI: https://doi.org/10.7759/cureus.6855

Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012;18(2)146-70. DOI: https://doi.org/10.1093/humupd/dmr042.

Mofid A, Seyyed Alinaghi SA, Zandieh S, Yazdani T. Hirsutism. Int J Clin Pract. 2008;62(3):433-43. DOI: https://doi.org/10.1111/j.1742-1241.2007.01621.x.

Hohl A, Ronsoni MF, Oliveira Md. Hirsutism: diagnosis and treatment. Arq Bras Endocrinol Metabol. 2014;58(2):97-107. DOI: https://doi.org/10.1590/0004-2730000002923

Willis SK, Mathew HM, Wise LA, Hatch EE, Wesselink AK, Rothman KJ. Menstrual pattern and self-reported hirsutism as assessed via the modified Ferriman-Gallwysacle: a cross-sectional estudy. Eur J Obst Gynecol Reprod Biol. 2020; 248:137-43. DOI: https://doi.org/10.1016/j.ejogrb.2020.03.012

Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440-7. DOI: http://dx.doi.org/10.1210/jcem-21-11-1440

Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006;19:210-23. DOI: https://doi.org/10.1111/j.1529-8019.2006.00077.x.

Madnani N, Khan K, Chauhan P, Parmar G. Polycystic ovarian syndrome. Indian J Dermatol Venereol Leprol. 2013;79:310-21. DOI: https://doi.org/10.4103/0378-6323.110759

Barba EJ. Síndrome de ovario poliquístico. Rev Mex Patol Clin Med Lab. 2019 [acceso: 24/09/2921];66(2):107-23. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=89321

Velásquez N, Fernández M, Briñez N. Manifestaciones dermatológicas del síndrome de ovario poliquístico. Rev Obstet Ginecol Venez. 2011 [acceso: 24/09/2921];71(4). Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0048-77322011000400007&lng=es.

Guerra Tapia A, González Guerra E, Borrás Schierloh JM. Alopecia androgénica femenina. Nuevos factores fisiopatogénicos y nuevas tendencias para el abordaje clínico integral. Mas Dermatol. 2016;26:25-36. DOI: https://doi.org/10.5538/1887-5181.2016.26.25

Wolf WM, Wattick RA, Kinkade ON, Olfert MD. The current description and future need for multidisciplinary PCOS. Review. Clinics J Clin Med. 2018;7(11)395. DOI: https://doi.org/10.3390/jcm7110395

Carmona Ruiz IO, Saucedo de la Llata E, Moraga-Sánchez MR. PCOS y fertilidad: una revisión de la evidencia actual. Rev. Iberoam. Fert Rep Hum. 2019 [acceso:24/09/2021];36:3-14. Disponible en: http://www.revistafertilidad.org/rif-articulos/-pcos-y-fertilidad--una-revisi-oacute-n-de-la-evidencia-actual--/285

Decanter C. Oocyte Quality in PCOS. En: S. Palomba (ed.). Infertility in Women with Polycystic Ovary Syndrome. 2018:31-9. DOI: https://doi.org/10.1007/978-3-319-45534-1

Chang RJ. The reproductive phenotype in polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007;3(10):688-95. DOI: https://doi.org/10.1038/ncpendmet0637.

Khomami M, Boyle JA, Tay CT, Vanky E, Teede HJ, Joham AE, et al. Polycystic ovary syndrome and adverse pregnancy outcomes: Current state of knowledge, challenges and potential implications for practice. Clin Endocrinol. 2018;88:761-9. DOI: https://doi.org/10.1111/cen.13579

Ozegowska K, Korman M, Szmyt A, Pawelczyk L. Heterogeneity of Endocrinologic and Metabolic Parameters in Reproductive Age Polycystic Ovary Syndrome (PCOS) Women Concerning the Severity of Hyperandrogenemia-A New Insight on Syndrome Pathogenesis. Int J Environ Res Public Health. 2020;17:9291. DOI: https://doi.org/10.3390/ijerph17249291

Alkhuriji AF, Al Omar SY, Babay ZA, El-Khadragy MF, Mansour LA, Alharbi WG, et al. Association of IL-1β, IL-6, TNF-α, and TGFβ1 Gene Polymorphisms with Recurrent Spontaneous Abortion in Polycystic Ovary Syndrome. Dis Markers. 2020;2020:6076274. DOI: https://doi.org/10.1155/2020/6076274.

Glintborg D, Andersen M. Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. Current Opinion in Obstetrics & Gynecology. 2017;29(6):390-6. DOI: https://doi.org/10.1097/gco.0000000000000410.

Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2019;92:108-20. DOI: https://doi.org/10.1016/j.metabol.2018.11.002.

Chitme HR, Al Azawi EA, Al Abri AM, Al Busaidi BM, Salam ZK, Al Taie MM, Al Harbo SK. Anthropometric and body composition analysis of infertile women with polycystic ovary syndrome. J Taibah Univ Med Sci. 2017 Jan 13;12(2):139-145. DOI: https://doi.org/10.1016/j.jtumed.2016.11.005.

Durmus U, Duran C, Ecirli S. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. J Endocrinol Invest. 2017;40(5):487-97. DOI: https://doi.org/10.1007/s40618-016-0582-x.

Jena D, Choudhury AK, Mangaraj S, Singh M, Mohanty BK, Baliarsinha AK. Study of Visceral and Subcutaneous Abdominal Fat Thickness and Its Correlation with Cardiometabolic Risk Factors and Hormonal Parameters in Polycystic Ovary Syndrome. Indian J Endocrinol Metab. 2018;22(3):321-7. DOI: https://doi.org/10.4103/ijem.IJEM_646_17.

Polak AM, Adamska A, Krentowska A, Łebkowska A, Hryniewicka J, Adamski M, et al. Body Composition, Serum Concentrations of Androgens and Insulin Resistance in Different Polycystic Ovary Syndrome Phenotypes. J Clin Med. 2020;9(3):732. DOI: https://doi.org/10.3390/jcm9030732.

Brennan KM, Kroener LL, Chazenbalk GD, Dumesic DA. Polycystic Ovary Syndrome: Impact of Lipotoxicity on Metabolic and Reproductive Health. Obstet Gynecol Surv. 2019;74(4):223-31. DOI: https://doi.org/10.1097/OGX.0000000000000661.

Lin K, Sun X, Wang X, Wang H, Chen X. Circulating Adipokine Levels in Nonobese Women with Polycystic Ovary Syndrome and in Nonobese Control Women: A Systematic Review and Meta-Analysis. Front Endocrinol. 2021;11:537809. DOI: https://doi.org/10.3389/fendo.2020.537809.

Spritzer P, Lecke S, Satler F, Morsch D. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015;149:219-27. DOI: https://doi.org/10.1530/REP-14-0435.

Zeng X, Xie Y, Liu Y, Long S, Mo Z. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214-21. DOI: https://doi.org/10.1016/j.cca.2019.11.003.

Bou Nemer L, Shi H, Carr BR, Word RA, Bukulmez O. Effect of Body Weight on Metabolic Hormones and Fatty Acid Metabolism in Follicular Fluid of Women Undergoing In Vitro Fertilization: A Pilot Study. Reprod Sci. 2019;26(3):404-11. DOI: https://doi.org/10.1177/1933719118776787.

Cena H, Chiovato L, Nappi R. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab. 2020;105:1-15. DOI: https://doi.org/10.1210/clinem/dgaa285.

Wilson NA, Peña AS. Quality of life in adolescent girls with polycystic ovary syndrome. J Pediatr Child Health. 2020;56(9):1351-7. DOI: https://doi.org/10.1111/jpc.15097.

Sidra S, Tariq MH, Farrukh MJ, Mohsin M. Evaluation of clinical manifestations, health risks, and quality of life among women with polycystic ovary syndrome. PLoS One. 2019;14(10):e0223329. DOI: https://doi.org/10.1371/journal.pone.0223329

Cesta CE, Månsson M, Palm C, Lichtenstein P, Iliadou AN, Landén M. Polycystic ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a nationwide Swedish cohort. Psychoneuroendocrinology. 2016;73:196-203. DOI: https://doi.org/10.1016/j.psyneuen.2016.08.005.

Baldani D, Skrgatic L, Kasum M, Zlopasa G, Oguic S, Herman M. Altered leptin, adiponectin, resistin and ghrelin secretion may represent an intrinsic polycystic ovary syndrome abnormality. Gynecol Endocrinol. 2019;35:401-5. DOI: https://doi.org/10.1080/09513590.2018.1534096.

Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;3(3):CD007506. DOI: https://doi.org/10.1002/14651858.CD007506.pub4

Skubleny D, Switzer NJ, Gill RS, Dykstra M, Shi X, Sagle MA, et al. The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis. Obes Surg. 2016;26(1):169-76. DOI: https://doi.org/10.1007/s11695-015-1902-5. 4.

Zore T, Joshi NV, Lizneva D, Azziz R. Polycystic Ovarian Syndrome: Long-Term Health Consequences. Semin Reprod Med. 2017;35(3):271-81. DOI: https://doi.org/10.1055/s-0037-1603096.

Joham AE, Boyle JA, Zoungas S, Teede HJ. Hypertension in reproductive-aged women with polycystic ovary syndrome and association with obesity. Am J Hypertens. 2015;28(7):847-51. DOI: https://doi.org/10.1093/ajh/hpu251.

Bajuk K, Pfeifer M. Cardiometabolic risk in polycystic ovary síndrome. Endoc Connect. 2018;7:238-51. DOI: https://doi.org/10.1530/EC-18-0129

Torchen LC. Cardiometabolic Risk in PCOS: More than a Reproductive Disorder. Curr Diab Rep. 2018;17(12):137. DOI: https://doi.org/10.1007/s11892-017-0956-2.

Gnanadass SA, Prabhu YD, Gopalakrishnan AV. Association of metabolic and inflammatory markers with polycystic ovarian síndrome (PCOS): an update. Arch Gynecol Obstet. 2021;303:631-43. DOI: https://doi.org/10.1007/s00404-020-05951-2.

Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Monthly. 2014;14:e23235. DOI: https://doi.org/10.5812/hepatmon.23235

Balachandran K, Sumilo D, O'Reilly MW, Toulis KA, Gokhale KM, Wijeyaratne CN, et al. Increased risk of obstructive sleep apnoea in women with polycystic ovary syndrome: a population- based cohort study. Eur J Endocrinol. 2019;180(4):265-72. DOI: https://doi.org/10.1530/EJE-18-0693.

Young HE, Ward WE. The relationship between Polycystic Ovarin Syndrome, Periodontal Disease, and Osteoporosis. Reprod Scienc. 2021;28:950-62. DOI: https://doi.org/10.1007/s43032-020-00310-7.

Osibogun O, Ogunmoroti O, Michos E. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020;30:399-404. DOI: https://doi.org/10.1016/j.tcm.2019.08.010.

Dahan MH, Abbasi F, Reaven GM. Cardiovascular disease in PCOS is related to severe insulin resistance, not mild. Minerva Endocrinol. 2017;42(3):294-6. DOI: https://doi.org/10.23736/S0391-1977.16.02482-2.

Mu L, Li R, Lai Y, Zhao Y, Qiao J. Adipose insulin resistance is associated with cardiovascular risk factors in polycystic ovary syndrome. J Endocrinol Invest. 2019;42(5):541-8. DOI: https://doi.org/10.1007/s40618-018-0949-2.

Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism. 2018;86:33-43. DOI: https://doi.org/10.1016/j.metabol.2017.09.016.

Yao K, Bian C, Zhao X. Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy (Review). Experim Therap Med. 2017;14:1271-6. DOI: https://doi.org/10.3892/etm.2017.4642.

Song D, Hong Y, Sung Y, Lee H. Insulin resistance according to β-cell function in women with polycystic ovary syndrome and normal glucose tolerance. PLoS ONE. 2017;12:e0178120. DOI: https://doi.org/10.1371/journal.pone.0178120.

Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981-1030. DOI: https://doi.org/10.1210/er.2011-1034.

Pasquali R. Metabolic Syndrome in Polycystic Ovary Syndrome. Horm Res. 2018;49:114-30. DOI: https://doi.org/10.1159/000485995

Monteagudo G, González R, Gómez M, Ovies G, Menocal A, Rodríguez K, et al. Resistencia a la insulina en mujeres con Síndrome de Ovario Poliquístico. Rev Cubana Endocrinol. 2019 [acceso: 09/07/2021];21(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532019000200004&lng=es&nrm=iso&tlng=es

Zhang L, Fang X, Li L, Liu R, Zhang C, Liu H, et al. The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome. J Endocrinol Invest. 2018;41(12):1401-7. DOI: https://doi.org/10.1007/s40618-018-0902-4.

Al-Jefout M, Alnawaiseh N, Al-Qtaitat A. Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes. Sci Rep. 2017;7(1):5339. DOI: https://doi.org/10.1038/s41598-017-05717-y.

Ollila MM, West S, Keinänen-Kiukaanniemi S, Jokelainen J, Auvinen J, Puukka K, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective, population-based cohort study. Hum Reprod. 2017;32(2):423-31. DOI: https://doi.org/10.1093/humrep/dew329.

González G, Rodríguez R, Ocampo J. Skin Manifestations of Insulin Resistance: From a Biochemical Stance to a Clinical Diagnosis and Management. Dermatol Ther (Heidelb). 2017;7:37-51. DOI: https://doi.org/10.1007/s13555-016-0160-3

Salley KE, Wickham EP, Cheang KL, Essay PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome–a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92(12):4546-56. DOI: https://doi.org/10.1210/jc.2007-1549.

Rubin KH, Glintborg D, Nybo M, Abrahamsen B, Andersen M. Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(10):3848-57. DOI: https://doi.org/10.1210/jc.2017-01354.

Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Human Reproduction. 2001;9:1995-8. DOI: https://doi.org/10.1093/humrep/16.9.1995

Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Current Diabetes Reports. 2006;1:77-83. DOI: https://doi.org/10.1007/s11892-006-0056-1

Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005;90(6):3236-42. DOI: https://doi.org/10.1210/jc.2004-1843

Meun C, Gunning MN, Louwers YV, Peters H, Roos‐Hesselink J, van Lennep JR, et al. The cardiovascular risk profile of middle‐aged women with polycystic ovary síndrome. Clin Endocrinol. 2020;92:150-8. DOI: https://doi.org/10.1111/cen.14117

Kakoly NS, Earnest A, Teede HJ, Moran LJ, Joham AE. The impact of obesity on the incidence of type 2 diabetes among women with polycystic ovary syndrome. Diabetes Care. 2019;42(4):560-7. DOI: https://doi.org/10.2337/dc18-1738.

Mustaniemi S, Vääräsmäki M, Eriksson JG, Gissler M, Laivuori H, Ljäs H, et al. Polycystic ovary syndrome and risk factors for gestational diabetes. Endocr Connect. 2018;7:859-69. DOI: https://doi.org/10.1530/EC-18-0076

Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607-13. DOI: https://doi.org/10.1016/s0002-9343(01)00948-2.

Macut D, Bjekic-Macut J, Savic-Radojevic A. Dyslipidemia and oxidative stress in PCOS. Front Hormone Res. 2013:40:51-63. DOI: https://doi.org/10.1159/000341683.

Marchesan LB, Spritzer PM. ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome. Fertility Sterility. 2019;111(3):579-87. DOI: https://doi.org/10.1016/j.fertnstert.2018.11.034.

Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347-63. DOI: https://doi.org/10.1093/humupd/dmq001.

Álvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. ArchInt Medic. 2006;166:2081. DOI: https://doi.org/10.1001/archinte.166.19.2081

Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154:141-5. DOI: https://doi.org/10.1530/eje.1.02058

Bil E, Dilbaz B, Cirik DA, Ozelci R, Ozkaya E, Dilbaz S. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype. J Obst Gynaecol Res. 2016;42:837-43. DOI: https://doi.org/10.1111/jog.12985

Ezeh U, Ida Chen YD, Azziz R. Racial and ethnic differences in the metabolic response of polycistic ovary síndrome. Clin Endocrinol. 2020;93(2):163-72. DOI: https://doi.org/10.1111/cen.14193

Kazemi M, Kim JY, Parry SA, Azziz R, Lujan ME. Disparities in cardio metabolic risk between Black and White women with polycystic ovary syndrome: a systematic review and meta-analysis. AJOG. 2021;224(5):428-44. DOI: https://doi.org/10.1016/j.ajog.2020.12.019

Zhu S, Zhang B, Jiang X, Li Z, Zhao S, Cui L, et al. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2019;111(1):168-77. DOI: https://doi.org/10.1016/j.fertnstert.2018.09.013.

Macut D, Bjekic-Macut J, Livadas S, Stanojlović O, Hrnčić D, Rašić-Marković A, et al. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. Curr Pharm Des. 2018;24(38):4593-7. DOI: https://doi.org/10.2174/1381612825666190117100751.

Macut D, Tziomalos K, Bozic-Antic I, Bjekic-Macut J, Katsikis I, Papadakis E, et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod. 2016;31:1347-53. DOI: https://doi.org/10.1093/humrep/dew076

Macut D, Božić-Antić I, Bjekić-Macut J, Tziomalos K. Management of endocrine disease: Polycystic ovary syndrome and nonalcoholic fatty liver disease. Eur J Endocrinol. 2017;177(3):R145-R58. DOI: https://doi.org/10.1530/EJE-16-1063.

Ayonrinde OT, Adams LA, Doherty DA, Mori TA, Beilin LJ, Oddy WH, et al. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys. J Gastroent Hepat. 2016;31:980-7. DOI: https://doi.org/10.1111/jgh.13241

Cree-Green M, Bergman BC, Coe GV, Newnes L, Baumgartner AD, Bacon S, et al. Hepatic steatosis is common in adolescents with obesity and PCOS and relates to de novo lipogenesis but not insulin resistance. Obesity. 2016;24:2399-2406. DOI: https://doi.org/10.1002/oby.21651

Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine. 2016;51:211-21. DOI: https://doi.org/10.1007/s12020-015-0640-8

Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical Epidemiology. 2014;6:1-13. DOI: https://doi.org/10.2147/CLEP.S37559.

Gómez-Acosta C, Vinaccia S, Quiceno M. El síndrome de ovario poliquístico: aspectos psicológicos. Rev Chil Obstet Ginecol. 2015;80(4):341-7. Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0717-75262015000400010&lng=es

Bhattacharya SM, Jha A. Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS). Fertil Steril. 2010;94:357-9. DOI: https://doi.org/10.1016/j.fertnstert.2009.09.025.

Kerchner A, Lester W, Stuart SP, Dokras A. Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertil Steril. 2009;91:207-12. DOI: https://doi.org/10.1016/j.fertnstert.2007.11.022.

Martino Pablo L, Bonet José L, De Bortoli M. Síndrome de ovario poliquístico: una revisión de sus correlatos patológicos en el ánimo y en el rendimiento cognitivo. Rev Chil Neuropsicolog. 2015 [acceso: 24/09/2021];10(1):38-43. Disponible en: https://www.redalyc.org/articulo.oa?id=179341106008.

Deeks A, Gibson-Helm M, Teede H. Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. Fertil Steril. 2010;93:2421-3. DOI: https://doi.org/10.1016/j.fertnstert.2009.09.018.

Stovall DW, Scriver JL, Clayton AH, Williams CD, Pastore LM. Sexual Function in Women with Polycystic Ovary Syndrome. J Sex Med. 2012;9(1):224-30. DOI: https://doi.org/10.1111/j.1743-6109.2011.02539.x.

Rodríguez M, Gempeler J, Pérez V, Ribero O. Síndrome de ovario poliquístico y su potencial asociación con trastorno bipolar en pacientes con trastorno del comportamiento alimentario. Rev Mex Trastor Aliment. 2017;8(2):142-50. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S2007-15232017000200142&lng=es

Annagür BB, Kerimoglu OS, Tazegül A, Gündüz S, Gencoglu BB. Psychiatric comorbidity in women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2015;41(8):1229-33. DOI: https://doi.org/10.1111/jog.12696.

Deeks AA, Gibson-Helm ME, Paul E, Teede HJ. Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression? Hum Reprod. 2011;26(6):1399-407. DOI: https://doi.org/10.1093/humrep/der071.

Bazarganipour F, Ziaei S, Montazeri A, Foroozanfard F, Kazemnejad A, Faghihzadeh S. Psychological investigation in patients with polycystic ovary syndrome. Health Quality Life Outcomes 2013;11:141. DOI: https://doi.org/10.1186/1477-7525-11-141.

Himelein M, Thatcher S. Depression and body image among women with polycystic ovary syndrome. J Health Psychol. 2006;11(4):613-25. DOI: https://doi.org/10.1177/1359105306065021.

Nasiri F, Ramezani F, Esmailzadeh S, Tohidi M, Azizi F, Basirat Z. Sexual function in women with polycystic ovary syndrome and their hormonal and clinical correlations. Int J Impot Res. 2018;30(2):54-61. DOI: https://doi.org/10.1038/s41443-017-0006-2.

Dashti S, Latiff LA, Hamid HA, Sani SM, Akhtari-Zavare M, Abu Bakar AS, et al. Sexual Dysfunction in Patients with Polycystic Ovary Syndrome in Malaysia. Asian Pac J Cancer Prev. 2016;17(8):3747-51. DOI: https://doi.org/10.21203/rs.2.11409/v1

Fliegner M, Richter-Appelt H, Krupp K, Brunner F. Sexual Function and Socio-Sexual Difficulties in Women with Polycystic Ovary Syndrome (PCOS). Geburtshilfe Frauenheilkd. 2019;79(5):498-509. DOI: https://doi.org/10.1055/a-0828-7901.

Trent M, Rich M, Austin B, Gordon C. Quality of Life in Adolescent Girls with Polycystic Ovary Syndrome. Arch Pediatr Adolesc Med. 2002 [acceso: 23/06/2021];156(6):556-60. Disponible en: https://pubmed.ncbi.nlm.nih.gov/12038887/

Schmid J, Kirchengast S, Vytiska-Binstorfer E, Huber J. Infertility caused by PCOS-health-related quality of life among Austrian and Moslem immigrant women in Austria. Hum Reprod. 2004 [acceso: 23/06/2021];19(10):2251-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/15333601/

Rzonca E, Bien A, Wdowiak A, Szymariski R, Iwanowicz P. Determinants of Quality of Life and satifaction with Life in Women with Polycystic Ovary Syndrome. Int J Environ Res Public Health. 2018 [cceso: 23/06/2021];15(2):376-85. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29470449/

Basheeruddin Asdaq SM, Jomah S, Hasan R, Al-Baroudi D, Alharbi M. Impact of polycystic ovary syndrome on eating behavior, depression and health related quality of life: A cross-sectional study in Riyadh. Saudi J Biol Sci. 2020 [acceso: 23/06/2021];27(12):3342-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33304140/

Ovies G, Pérez A, Domínguez E. Calidad de vida en mujeres con síndrome de ovario poliquístico. [Tesis de grado]. La Habana: Universidad de Ciencias Médicas; 2020.

Yao K, Bian C, Zhao X. Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy. Exp Ther Med. 2017;14(2):1271-6. DOI: https://doi.org/10.3892/etm.2017.4642.

Zhang L, Zheng W, Liu C, Liang X, Zhang L, Tian Z, et al. Associations between pre-pregnancy body mass index and gestational weight gain with pregnancy outcomes in women with polycystic ovary syndrome. Diabetol Metab Syndr. 2020;12:88. DOI: https://doi.org/10.1186/s13098-020-00595-3.

Carmina E, Lobo RA. Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome? J Womens Health (Larchmt). 2018;27(11):1385-8. DOI: https://doi.org/10.1089/jwh.2018.7162.

Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol. 2018;17(1):37. DOI: https://doi.org/10.1186/s12933-018-0680-5.

Oncul M, Uzun H. Polycystic ovary syndrome and endotelial dysfunction: A potencial role for soluble lectin-like oxidized low density lipoprotein receptor-1. Reprod Biol. 2020;20(3):396-401. DOI: https://doi.org/10.1016/j.repbio.2020.04.006

Zhao L, Zhu Z, Lou H, Zhu G, Huang W, Zhang S, et al. Polycystic ovary syn- drome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget. 2016;7(23):33715-21. DOI: https://doi.org/10.18632/oncotarget.9553.

Zhou Y, Wang X, Jiang Y, Ma H, Chen L, Lai C, et al. Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: insights from a meta-analysis. Gynecol Endocrinol. 2017;33(12):904-10. DOI: https://doi.org/10.1080/09513590.2017.1347779.

Trost LW, Mulhall JP. Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials. J Sex Med. 2016;13(7):1029-46. DOI: https://doi.org/10.1016/j.jsxm.2016.04.068.

Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28-38.e25. DOI: https://doi.org/10.1016/j.fertnstert.2011.09.024.

Martin KA. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(4):1105-20. DOI: https://doi.org/10.1210/jc.2007-2437.

Taieb J, Mathian B, Millot F, Patricot M, Mathieu E, Queyrel N, et al. Testosterone measurement by 10 immunoassays and isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women and children. Clin Chem. 2003;49(8):1381-95. DOI: https://doi.org/10.1373/49.8.1381.

Trent M, Gordon C. Diagnosis and Management of Polycystic Ovary Syndrome in Adolescents. Pediatrics 2020;145(Suppl 2):S210-S8. DOI: https://doi.org/10.1542/peds.2019-2056J

Peña AS, Witchel SF, Hoeger KM, Oberfield SF, Vogiatzi MG, Misso M, et al. Adolescent polycystic ovary síndrome according to the international evidence based guideline. BMC Med. 2020;18(1):72. DOI: https://doi.org/10.1186/s12916-020-01516-x.

Morán C, Hernández M, Cravioto M, Porias HL, Malacara JM, Bermúdez JA. Síndrome de Ovario Poliquístico. Posición De La Sociedad Mexicana de Nutrición y Endocrinología. Rev Endocrinol Nutr. 2006 [acceso: 10/05/2021];14(1):7-12. Disponible en: https://www.medigraphic.com/pdfs/endoc/er-2006/er061b.pdf

Fox R, Corrigan E, Thomas PA, Hull MG. The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: predictive power of endocrine tests. Clin Endocrinol (Oxf). 1991;34(2):127-31. DOI: https://doi.org/10.1111/j.1365-2265.1991.tb00282.x.

Nisenblat V, Norman R. Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabet Obes. 2009;16(3):224-31. DOI: https://doi.org/10.1097/MED.0b013e32832afd4d.

Saucedo de la Llata E, Moraga Sánchez MR, Romeu Sarrió A, Carmona Ruiz IO. Proporción LH-FSH y síndrome de ovario poliquístico: ¿prueba olvidada o no útil? Ginecol Obstet Mex. 2016 [acceso: 02/04/2021];84(2):84-94. Disponible en: https://www.medigraphic.com/pdfs/ginobsmex/gom-2016/gom162e.pdf

Delcour C, Robin G, Young J, Dewailly D. PCOS and Hyperprolactinemia: what do we know in 2019?. Clin Med Insights Reprod Health. 2019;13:1179558119871921. DOI: https://doi.org/10.1177/1179558119871921

Kyritsi EM, Dimitriadis GK, Angelousi A, Mehta H, Shad A, Mytilinaiou M, et al. The value of prolactin in predicting prolactinoma in hyperprolactinaemic polycystic ovarian syndrome. Eur J Clin Invest. 2018;48(7):e12961. DOI: https://doi.org/10.1111/eci.12961

Tam M, Le MT, Le VNS, Le DD, Nguyen VQH, Chen C, et al. Exploration of the role of anti‐Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome. Clin Endocrinol (Offo). 2019;90(4):579-585. DOI: https://doi.org/10.1111/cen.13934.

Singh AK, Singh R. Can anti-Mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress. Indian J Endocr Metab. 2015 [acceso: 10/05/2021];19:731-43. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673800/pdf/IJEM-19-731.pdf

Dewailly D, Robin G, Peigne M, Decanter C, Pigny P, Catteau-Jonard S. Interactions between androgens, FSH, anti-müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update. 2016;22(6):709-24. DOI: https://doi.org/10.1093/humupd/dmw027.

Li L, Chen X, Mo Y, Chen Y, Wenig M, Yang D. Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr. 2010;122(17-18):519-24. DOI: https://doi.org/10.1007/s00508-010-1426-x.

XiW, Yang Y, Mao H, Zhao X, Liu M, Fu S. Circulating anti-mullerian hormone as predictor of ovarian response to clomiphene citrate in women with polycystic ovary syndrome. J Ovarian Res. 2016;9(3). DOI: https://doi.org/10.1186/s13048-016-0214-2

Vitale SG, Riemma G, Cianci A. Antimüllerian hormone in polycystic ovarian syndrome: from a key role in the pathogenesis to a sentinel for pre-term birth prediction. Fertil Steril. 2020;113(2):335-6. DOI: https://doi.org/10.1016/j.fertnstert.2019.10.036.

Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes. 2010;59(11):2697-707. DOI: https://doi.org/10.2337/db10-1032.

Tosi F, Bonora E, Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod. 2017;32(12):2515-21. DOI: https://doi.org/10.1093/humrep/dex308.

De Souza AL, Batista GA, Alegre SM. Assessment of insulin sensitivity by the hyperinsulinemic euglycemic clamp: Comparison with the spectral analysis of photoplethysmography. J Diabetes Complications. 2017;31(1):128-33. DOI: https://doi.org/10.1016/j.jdiacomp.2016.10.018.

Dahan M, Reaven G. Relationship among obesity, insulin resistance, and hyperinsulinemia in the polycystic ovary syndrome. Endocrine. 2019;64:685-9. DOI: https://doi.org/10.1007/s12020-019-01899-9

Cassar S, Teede HJ, Harrison CL, Joham AE, Moran LJ, Stepto NK. Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity. Clin Endocrinol (Oxf). 2015;83(1):50-8. DOI: https://doi.org/10.1111/cen.12619.

Shahin L, Hyassat D, Batieha A, Khader Y, El-Khateeb M, Ajlouni K. Insulin Sensitivity Indices in Patients with Polycystic Ovary Syndrome with Different Body Mass Index Categories. Curr Diabetes Rev. 2020;16(5):483-9. DOI: https://doi.org/10.2174/1573399815666190823151222.

Søndergaard E, Espinosa De Ycaza AE, Morgan-Bathke M, Jensen MD. How to Measure Adipose Tissue Insulin Sensitivity. J Clin Endocrinol Metab. 2017;102(4):1193-9. DOI: https://doi.org/10.1210/jc.2017-00047.

Polak K, Czyzyk A, Simoncini T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 2017;40:1-8. DOI: https://doi.org/10.1007/s40618-016-0523-8.

Li L, Zhang J, Zeng J, Liao B, Peng X, Li T, et al. Proteomics analysis of potential serum biomarkers for insulin resistance in patients with polycystic ovary syndrome. Int J Mol Med. 2020;45:1409-16. DOI: https://doi.org/10.3892/ijmm.2020.4522.

Pollak F. Resistencia a la insulina: Verdades y controversias. Rev Med Clin Condes 2016;27(2):171-8. DOI: https://doi.org/10.1016/j.rmclc.2016.04.006

Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014;20(3):334-52. DOI: https://doi.org/10.1093/humupd/dmt061.

Goodman N, Cobin R, Walter F, Futterweit W, Glueck J, Legro R, et al. American Association of Clinical Endocrinologist, American College of Endocrinologist, Androgen Excess and PCOS Society Disease State Clinical Review. Guide to The Best Practices in the evaluation and treatment of polycystic ovary syndrome. Part 1. Endocrine Practice. 2015;21(11):1291-300. DOI: https://doi.org/10.4158/EP15748.DSC.

Lujan ME, Jarrett BY, Brooks ED, Reines JK, Peppin AK, Muhn N, et al. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod. 2013;28(5):1361-8. DOI: https://doi.org/10.1093/humrep/det062.

Allemand MC, Tummon IS, Phy JL, Foong SC, Dumesic DA, Session DR. Diagnosis of polycystic ovaries by three-dimensional transvaginal ultrasound. Fertil Steril. 2006;85(1):214-9. DOI: https://doi.org/10.1016/j.fertnstert.2005.07.1279.

Christ JP, Willis AD, Brooks ED, Vanden H, Jarrett BY, Pierson RA, et al. Follicle number, and not assessments of the ovarian stroma, represents the best ultrasonographic marker of polycystic ovary syndrome. Fertil Steril. 2014;101(1):280-7.e1. DOI: https://doi.org/10.1016/j.fertnstert.2013.10.001.

Sujata K, Swoyam S. 2D and 3D Trans-vaginal Sonography to Determine Cut-offs for Ovarian Volume and Follicle Number per Ovary for Diagnosis of Polycystic Ovary Syndrome in Indian Women. J Reprod Infertil. 2018 [acceso: 20/06/2021];19(3):146-51. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104427/

Mendoza Rivas A. Diagnóstico ecográfico del síndrome de ovario poliquístico. Rev Obstet Ginecol Venez. 2016 [acceso: 20/10/2021];76(Suppl 1):S35-S8. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0048-77322016000300007&lng=es.

Moschos E, Twickler DM. Prediction of polycystic ovarian syndrome based on ultrasound findings and clinical parameters. J Clin Ultrasound. 2015;43(3):157-63. DOI: https://doi.org/10.1002/jcu.22182.

Van Schoubroeck D, Raine-Fenning N, Installé AJ, De Neubourg D, De Moor B, Bourne T, et al. Interobserver agreement in assessment of polycystic ovarian morphology using pattern recognition. Ultrasound Obstet Gynecol. 2016;47(5):652-3. DOI: https://doi.org/10.1002/uog.15768.

Welt C, Carmina E. The lifecycle of PCOS. J Clinic Endocrinolog Metabol. 2013;98(12):4629-38. DOI: https://doi.org/10.1210/jc.2013-2375.

Brown ZA, Louwers YV, Fong SL, Valkenburg O, Birnie E, de Jong FH, et al. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil Steril. 2011;96(5):1259-65. DOI: https://doi.org/10.1016/j.fertnstert.2011.09.002.

Liang SJ, Hsu CS, Tzeng CR, Chen CH, Hsu MI. Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40. Hum Reprod. 2011;26(12):3443-9. DOI: https://doi.org/10.1093/humrep/der302.

Carmina E, Campagna AM, Lobo RA. A 20-year follow-up of young women with polycystic ovary syndrome. Am J Obstet Gynecol. 2012;119(2):263-9. DOI: https://doi.org/10.1097/AOG.0b013e31823f7135.

Barbieri R, Ehrmann D. Treatment of polycystic ovary syndrome in adults. 2020 [acceso: 20/10/2021]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK278959/

Mariani G, Bellver J. Management Options for Infertile Women with Polycystic Ovary Syndrome. US Endocrinology. 2018;14(2):67-72. DOI: https://doi.org/10.17925/USE.2018.14.2.67

Orias Vásquez M. Actualización del síndrome de ovario poliquístico. Rev Med Sinerg. 2021 [acceso: 20/10/2021];6(2):e648. Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/648

Sanchez Gaitan E. Actualización del manejo de síndrome de ovario poliquístico. Rev Med Sinerg. 2019 [acceso: 10/03/2020];4(12):e322. Disponible en: https://revistamedicasinergia.com/index.php/rms

Ruiz Rodríguez R, Serrano Mera VK, Solis Guzmán PG, Montes Mendoza GA. Síntomas y tratamiento de pacientes diagnosticadas con síndrome de ovario poliquístico. RECIAMUC. 2021;4(4):125-33. DOI: https://doi.org/10.26820/reciamuc/4.

Boyd M, Ziegler J. Polycystic Ovary Syndrome, Fertility, Diet, and Lifestyle Modifications. Top Clin Nutr. 2019; 34(1):14-30. DOI: https://doi.org/10.1097/TIN.0000000000000161

De Sousa S, Norman R. Metabolic syndrome, diet and exercise. Best Practice Research Clinical Obstetrics & Gynaecology. 2016 [acceso: 10/06/2021];37:140-151. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1521693416000079?via%3Dihub

Pasquali R. Contemporary approaches to the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2018;9(4):123-34. DOI: https://doi.org/10.1177/2042018818756790.

Tay CT, Joham AE, Hiam DS, Gadalla MA, Pundir J, Thangaratinam S, et al. Pharmacological and surgical treatment of non-reproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. Clin Endocrinol. 2018;89:535-53. DOI: https://doi.org/10.1111/cen.13753

Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84. DOI: https://doi.org/10.1038/nrendo.2018.24.

Ablan Franklin, Nottola Nilfran. Tratamiento del síndrome de ovario poliquístico: Antiandrógenos. Rev Venez Endocrinol Metab. 2007 [acceso: 10/05/2021];5(3):64-6. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S1690-31102007000300016&lng=es.

Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol. 2020;13(1):53-64. DOI: https://doi.org/10.1080/17512433.2020.1698291.

Pundir J, Charles D, Sabatini L, Hiam D, Jitpiriyaroj S, Teede H, et al. Overview of systematic reviews of non-pharmacological interventions in women with polycystic ovary syndrome. Hum Reprod Update 2019;25(2):243-56. DOI: https://doi.org/10.1093/humupd/dmy045.

Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003;361(9372):1894-901. DOI: https://doi.org/10.1016/S0140-6736(03)13493-9.

Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30(1):1-50. DOI: https://doi.org/10.1210/er.2008-0030.

Artani M, Iftikhar M, Khan S. Effects of Metformin on Symptoms of Polycystic Ovarian Syndrome Among Women of Reproductive Age. Cureus. 2018;10(8):e3203. DOI: https://doi.org/10.7759/cureus.3203

Glintborg D, Andersen M. Morbidity in polycystic ovary syndrome. Eur J Endocrinol. 2017;176(2):R53-R65. DOI: https://doi.org/10.1530/EJE-16-0373.

Orio F, Muscogiuri G, Nese C, Palomba S, Savastano S, Tafuri D, et al. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an update in the management of polycystic ovary syndrome. Eur J Obstet Gynecol. 2016;207:214-9. DOI: https://doi.org/10.1016/j.ejogrb.2016.08.026.

Franik G, Bizoń A, Włoch S, Pluta D, Blukacz L, Milnerowicz H. The effect of abdominal obesity in patients with polycystic ovary syndrome on metabolic parameters. Eur Rev Med Pharmacol Sci. 2017 [20/10/2021];21:4755-61. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29164590/

Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligoamenorrhoea and subfertility. Cochrane Systematic Review. 2017 [acceso: 10/06/2021] Disponible en: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003053.pub6.

Ehrmann MD. Metformin for treatment of the polycystic ovary syndrome. 2020 [acceso: 20/10/2021]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/14973411/

Zeng X, Xie Y, Liu Y, Long S, Mo Z. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214-21. DOI: https://doi.org/10.1016/j.cca.2019.11.003

Yao K, Bian C, Zhao X. Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy. Exp Ther Med. 2017;14(2):1271-6. DOI: https://doi.org/10.3892/etm.2017.4642.

Jacobs M, Bazzano L, Pridjian G, Harville E. Childhood adiposity and fertility difficulties: The Bogalusa Heart Study. Pediatr Obes. 2017;12:477-84. DOI: https://doi.org/10.1111/ijpo.12168

Liu X, Zhang Y, Zheng SY. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;87(6):767-74. DOI: https://doi.org/10.1111/cen.13454.

Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2019;12:CD013505. DOI: https://doi.org/10.1002/14651858.CD013505.

Facchinetti F, Appetecchia M, Aragona C, Bevilacqua A, Bezerra MS. Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. Expert Opin Drug Metabol Toxicol. 2020;16(3):255-74. DOI: https://doi.org/10.1080/17425255.2020.1737675.

Wojciechowska A, Osowski A, Jó´zwik M, Górecki R, Rynkiewicz A, Wojtkiewicz J. Inositols’ Importance in the Improvement of the Endocrine–Metabolic Profile in PCOS. Int J Mol Sci. 2019;20(22):5787-6004. DOI: https://doi.org/10.3390/ijms20225787

Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update. 2004;10(2):107-17. DOI: https://doi.org/10.1093/humupd/dmh010.

Mejías Quintero ME. Síndrome de ovario poliquístico e infertilidad: Opciones de tratamiento. Rev Obstet Ginecol Venez. 2015 [acceso: 20/06/2021];75(4):269-79. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0048-77322015000400007&lng=en.

Mejia RB, Summers KM, Kresowik JD, Van Voorhis BJ. A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2019;111(3):571-8.e1. DOI: https://doi.org/10.1016/j.fertnstert.2018.11.030.

Salazar-Ortiz DY, Rodríguez-Antonio M, Contreras-Carreto NA. Comparación de la eficacia de citrato de clomifeno vs. letrozol en mujeres con infertilidad por síndrome de ovario poliquístico. Ginecol Obstet Mex. 2016 [cceso: 20/05/2021];84(11):696-703. Dispnible en: https://www.medigraphic.com/pdfs/ginobsmex/gom-2016/gom1611d.pdf

Franik S, Eltrop SM, Kremer JM, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2018;5:CD010287. DOI: https://doi.org/10.1002/14651858.CD010287.pub3

Weiss NS, Kostova E, Nahuis M, Mol BJ, van der Veen F, van Wely M. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. Cochrane Database Systemat Reviews. 2019;1:CD010290. DOI: https://doi.org/10.1002/14651858.CD010290.pub3

Amer S, Li TC, Cooke ID. A prospective dose-finding study of the amount of thermal energy required for laparoscopic ovarian diathermy. 2003;18(8):1693-8. DOI: https://doi.org/10.1093/humrep/deg307.

Gaona R. Una nueva época para el tratamiento quirúrgico del ovario en el síndrome de ovario poliquístico. Rev Endocrinolog Nutric. 2006 [acceso: 20/06/2021];14(1):25-32. Disponible en: https://www.medigraphic.com/pdfs/endoc/er-2006/er061e.pdf

Espinós Gómez JJ, Polo Ramos A. Estudio y tratamiento de la anovulación en el síndrome de ovarios poliquísticos. 2020. Disponible en: https://docplayer.es/34279783-Guia-7-estudio-y-tratamiento-de-la-anovulacion-en-el-sindrome-de-ovarios-poliquisticos.html

Xu B, Zhou M, Cheng M, Zhang D, Wu X, Si C, et al. Transvaginal ovarian drilling followed by controlled ovarian stimulation from the next day improves ovarian response for the poor responders with polycystic ovary syndrome during IVF treatment: a pilot study. Reprod Biol Endocrinol. 2020;18:7-16. DOI: https://doi.org/10.1186/s12958-019-0559-7

Sebastian MR, Wiemann CM, Bacha F, Alston Taylor SJ. Diagnostic evaluation, comorbidity screening, and treatment of polycystic ovary syndrome in adolescents in 3 specialty clinics. J Pediatr Adolesc Gynecol. 2018;31(4):367-71. DOI: https://doi.org/10.1016/j.jpag.2018.01.007.

Ibanez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Hormone Res Paediatr. 2017;88(6):371-95. DOI: https://doi.org/10.1159/000479371.

Nguyen L, Chan SA, Keong Teo AK. Metformin from mother to unborn child Are there unwarranted effects? E Bio Medicine. 2018;35:394-404. DOI: https://doi.org/10.1016/j.ebiom.2018.08.047.

Liu W, Yang M. The pros and cons of application of metformin in the pregnant women with polycystic ovary syndrome. Chinese J Endocrinol Metabol. 2018;34(10):809-13. DOI: https://doi.org/10.3760/cma.j.issn.1000-6699.2018.10.001

Butalia S, Gutierrez L, Lodha A, Aitken E, Zakariasen A, Donovan L. Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. Diabet Med. 2017;34(1):27-36. DOI: https://doi.org/10.1111/dme.13150.

Singh N, Madhu M, Vanamail P, Malik N, Kumar S. Efficacy of metformin in improving glycaemic control & perinatal outcome in gestational diabetes mellitus: A non-randomized study. Indian J Med Res. 2017;145(5):623-8. DOI: https://doi.org/10.4103/ijmr.IJMR_1358_15.

Scherneck S, Schlinke N, Beck E, Grupe K, Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study. Reprod Toxicology. 2018;81:79-83. DOI: https://doi.org/10.1016/j.reprotox.2018.07.004.

Cruz J, Piloto M. Segundo Consenso Cubano de Diabetes y Embarazo. Rev Cubana Endocrinol. 2018 [acceso: 20/06/2021];29(1). Disponible en: http://www.revendocrinologia.sld.cu/index.php/endocrinologia/article/view/97/86.

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2023 Gilda Monteagudo Peña, Gisel Ovies Carballo, Manuel Gomez Alzugaray, Maite Cabrera Gaméz, Kenia Rodríguez Matínez

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.